Milestone Investment Advisors LLC Makes New $535,000 Investment in Johnson & Johnson (NYSE:JNJ)

Milestone Investment Advisors LLC bought a new position in Johnson & Johnson (NYSE:JNJFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,435 shares of the company’s stock, valued at approximately $535,000.

A number of other hedge funds have also modified their holdings of JNJ. Rather & Kittrell Inc. raised its stake in Johnson & Johnson by 2.0% during the 2nd quarter. Rather & Kittrell Inc. now owns 2,909 shares of the company’s stock worth $481,000 after buying an additional 58 shares during the period. Capital Square LLC raised its stake in Johnson & Johnson by 1.4% during the 2nd quarter. Capital Square LLC now owns 4,245 shares of the company’s stock worth $703,000 after buying an additional 58 shares during the period. Wagner Wealth Management LLC raised its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. Wagner Wealth Management LLC now owns 4,543 shares of the company’s stock valued at $752,000 after purchasing an additional 59 shares during the period. Chesapeake Wealth Management raised its stake in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Chesapeake Wealth Management now owns 9,196 shares of the company’s stock valued at $1,522,000 after purchasing an additional 60 shares during the period. Finally, RPG Investment Advisory LLC raised its stake in shares of Johnson & Johnson by 1.2% in the 2nd quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock valued at $807,000 after purchasing an additional 60 shares during the period. 68.40% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.2 %

NYSE JNJ opened at $156.76 on Monday. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The stock has a 50 day moving average of $158.20 and a 200-day moving average of $158.73. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. The company has a market cap of $377.37 billion, a PE ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business had revenue of $21.40 billion for the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the prior year, the business earned $2.35 EPS. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Wall Street Analyst Weigh In

Several analysts have issued reports on JNJ shares. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Morgan Stanley dropped their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Finally, Raymond James raised their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $176.14.

View Our Latest Analysis on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.